Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 3Gynecologic 1

Conditions

Colorectal Neoplasms 19Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Non-Small-Cell Lung 9Neoplasms 7Colonic Neoplasms 6Mouth Neoplasms 5Rectal Neoplasms 4Lung Neoplasms 4Carcinoma, Squamous Cell 4Carcinoma 4Pancreatic Neoplasms 3Neoplasm Metastasis 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Head and Neck Neoplasms 3Thyroid Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oropharyngeal Neoplasms 2Breast Neoplasms 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms by Site 1

Interventions

Specimen Handling 20Gemcitabine 18Magnetic Resonance Spectroscopy 12Biopsy 12Leucovorin 10Irinotecan 10Fluorouracil 10130-nm albumin-bound paclitaxel 10Albumin-Bound Paclitaxel 8Oxaliplatin 7Taxes 6pembrolizumab 5Nivolumab 5irinotecan sucrosofate 4fludarabine 4dehydroftorafur 4Radiosurgery 4Ipilimumab 4Cyclophosphamide 4Capecitabine 4aldesleukin 3Radiotherapy 3Radiation 3Exercise 3Cisplatin 3Cetuximab 3veliparib 2trametinib 2quemliclustat 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Cetuximab × 30 days × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07300150 2026-05-07

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

PAQ Therapeutics, Inc.

Phase 1 Recruiting
195 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06835569 2026-05-06

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Alterome Therapeutics, Inc.

Phase 1 Recruiting
188 enrolled
GastrointestinalThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡